natgillin/translations-raw huggingface dataset:
Generelt var patienter, der udviklede ALAT og ASAT stigninger, asymptomatiske, og hæ ndelserne bedredes eller forsvandt med enten fortsæ ttelse eller afbrydelse af infliximab, eller justering af samtidig behandling.
In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of infliximab, or modification of concomitant therapy.
Generelt var procentdelen af antistofpositive patienter ens på tværs af de kliniske studier.
Overall the percentage of antibody positive patients was consistent across clinical trials.
Generelt var procentdelen af antistofpositive patienter ens på tværs af de kliniske studier.
Overall, the percentage of antibody positive patients was consistent across clinical trials.
Generelt var sikkerhedsprofilen for ISENTRESS hos patienter med hepatitis B- og/eller hepatitis C--viruskoinfektion den samme som hos patienter uden hepatitis B og/eller hepatitis C viruskoinfektion, selvom hyppigheden af uregelmæssigheder vedrørende ASAT og ALAT var noget højere i undergruppen med hepatitis B- og/eller hepatitis C-viruskoinfektion i begge behandlingsgrupper.
In general the safety profile of ISENTRESS in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co- infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup with hepatitis B and/or hepatitis C virus co-infection for both treatment groups.
Generelt var sikkerhedsprofilen for ISENTRESS hos patienter med hepatitis B- og/eller hepatitis C-viruskoinfektion den samme som hos patienter uden hepatitis B- og/eller hepatitis C-viruskoinfektion, selvom hyppigheden af uregelmæssigheder vedrørende ASAT og ALAT var noget højere i undergruppen med hepatitis B- og/eller hepatitis C-viruskoinfektion i begge behandlingsgrupper.
In general the safety profile of ISENTRESS in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co- infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup with hepatitis B and/or hepatitis C virus co-infection for both treatment groups.
Generelt var sikkerhedsprofilen for raltegravir hos patienter med hepatitis B- og/eller hepatitis C-virusco- infektion den samme som hos patienter uden hepatitis B og/eller hepatitis C-virusco-infektion, selvom hyppigheden af uregelmæssigheder vedrørende ASAT og ALAT var noget højere i undergruppen med hepatitis B- og/eller hepatitis C-virusco-infektion i begge behandlingsgrupper.
In general the safety profile of raltegravir in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup with hepatitis B and/or hepatitis C virus co-infection for both treatment groups.
Generelt var værdierne for GnRH- antagonisterne en smule højere.
Overall, the values for the GnRH agonists were slightly higher.
Generelt ved beslutning om anvendelse af antiretrovirale lægemidler til behandling af hiv-infektion hos gravide for dermed at reducere risikoen for vertikal overførsel af hiv til det nyfødte barn bør data både fra dyrestudier og klinisk erfaring hos gravide tages i betragtning for at kunne beskrive sikkerheden for fostret.
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account in order to characterise the safety for the foetus.
Generelt viste færre Ferriprox-behandlede patienter end deferoxamin-behandlede patienter en forværring af den kardiale dysfunktion fra første vurdering til sidste vurdering (4% vs.
Overall, fewer Ferriprox-treated patients than deferoxamine-treated patients showed a worsening of cardiac dysfunction from first assessment to last assessment (4% vs.
Generelt: besvær med at trække vejret og synke; svulst i skjoldbruskkirtlen; infektion i blodet; hævelse eller knuder i kroppens organer; sygdom, der fører til tiltagende muskellammelse; sygdom i hjernen – tegnene kan være hovedpine og feber, lammelse af dele af kroppen, stiv nakke eller lysfølsomhed
General: difficult breathing and swallowing; tumour of the thyroid; infection of the blood; swelling or lumps in organs of the body; disease which leads to increasing muscle paralysis; disease of the brain – signs may include headache and fever, paralysis of a part of the body, a stiff neck or being sensitive to light
Generelt: feber, hovedpine, træthed, svimmelhed eller besvimelse, mørkfarvet urin, blødning, svaghedsfølelse, følelsesløshed i ben, arme eller ansigt, adfærdsændringer som f.eks. mindre sexlyst, irritabilitet eller glemsomhed
General: fever, headache, feeling tired, dizziness or fainting, dark urine, bleeding, weakness, numbness of legs, arms, or faces, changes in behavior, such as less sex drive, being irritable or forgetful
Generelt: Generel forværring af tilstand, vægtøgning, rødme og hævelse på injektionsstedet, cancersmerter og blødning, organsvigt af flere organer
General: general condition worsening, weight increase, redness and swelling at the injection site, cancer pain and bleeding, multiple organ failure
Generelt: Hos patienter, hvis vaskulære tonus og nyrefunktion hovedsageligt afhænger af renin- angiotensin-aldosteronsystemets aktivitet (fx patienter med alvorlig hjerteinsufficiens eller underliggende nyresygdom, inklusive nyrearteriestenose), er behandling med angiotensin- konverterende enzymhæmmere eller angiotensin-II receptorantagonister, der påvirker dette system, blevet forbundet med akut hypotension, azotæmi, oliguri og i sjældne tilfælde akut nyresvigt.
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure.
Generelt: Hos patienter, hvis vaskulære tonus og nyrefunktion hovedsageligt afhænger af renin- angiotensin-aldosteronsystemets aktivitet, (fx patienter med alvorlig hjerteinsufficiens eller underliggende nyresygdom, inklusive nyrearteriestenose), er behandling med angiotensin- konverterende enzymhæmmere eller angiotensin-II receptorantagonister, der påvirker dette system, blevet forbundet med akut hypotension, azotæmi, oliguri og i sjældne tilfælde med akut nyresvigt (se pkt.
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure.
Generelt: Hos patienter, hvis vaskulære tonus og nyrefunktion hovedsageligt afhænger af renin- angiotensin-aldosteronsystemets aktivitet, (fx patienter med alvorlig hjerteinsufficiens eller underliggende nyresygdom, inklusive nyrearteriestenose), er behandling med angiotensin- konverterende enzymhæmmere eller angiotensin-II receptorantagonister, der påvirker dette system, blevet forbundet med akut hypotension, azotæmi, oliguri og i sjældne tilfælde med akut nyresvigt.
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotaemia, oliguria, or rarely acute renal failure.
Generelt: rysten; besvimelse; vejrtrækningsbesvær; tørstfølelse; søvnbesvær; dunkende hovedpine; generel utilpashed; følelse af, alt snurrer rundt
General: shaking; fainting; difficulty breathing; feeling thirsty; trouble sleeping; throbbing headache; generally feeling unwell; feeling like you are spinning
Generelt: svimmelhed, leddegigt; øget tilbøjelighed til at bløde; hævede kirtler i halsen eller under armene eller i lysken; kraftig brænden eller stikkende smerte; øget følsomhed over for lys, lyd, det, man kan føle eller den mad, man smager; sukkersyge (diabetes mellitus)
General: light-headedness, arthritis; increased tendency to bleed; swollen glands in neck or armpit or groin; intense burning or stabbing pain; increased sensitivity to light, sound, what is felt, or food one tastes; diabetes
Generelt: Targretin-kapsler bør anvendes med forsigtighed hos patienter med kendt overfølsomhed overfor retinoider.
General: Targretin capsules should be used with caution in patients with a known hypersensitivity to retinoids.
Generelt^
Overall^
Generelt‡
Overall
Generende og langstrakt menstruation, abnorm menstruation, ømme bryster, uregelmæssig menstruation, udflåd fra skeden, nedsat sexlyst
Heavy and prolonged period, abnormal period, breast tenderness, irregular periods, discharge from vagina, decreased sex drive
Generics [UK] Limited
METHOD AND ROUTEOF ADMINISTRATION
Generics [UK] Limited Station Close
Generics [UK] Limited, Station Close,
Generics [UK] Limited, Potters Bar, Hertfordshire, EN6 1TL, Storbritannien.
Generics [UK] Limited, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom.
Generics [UK] Limited, Station Close, Potters Bar, Hertfordshire, EN6 1TL, Storbritannien
Generics [UK] Limited, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
Generics [UK] Ltd Tel: +44 1707 853000 (Lielbritānija)(United Kingdom)
Generics [UK] Ltd Tel: +44 1707 853000 (Lielbritānija)
Generics [UK] Ltd Tel: +44 1707 853000 (United Kingdom) (Ühendkuningriik)
Generics [UK] Ltd Tel: +44 1707 853000 (Ühendkuningriik)
Generics [UK] LtdGSP Proizvodi d.o.o Tél: +44 1707 853000386 1 236 31 85 (United Kingdom)
GSP Proizvodi d.o.o Tél: +386 1 236 31 85
Generics [UK] LtdLjubomir Marcov
Ljubomir Marcov
Generics [UK] LtdMylan bvba/sprl Tél/Tel: +44 1707 85300032 02 658 61 00 (United KingdomBelgique/Belgien)
Tel: +32 02 658 61 00 (Belgique/Belgien)
Generics [UK]Eisai Ltd.
Generics [UK] Ltd.
Generics [UK]LimitedA&G Med Trading SRL Tel: + 44 1707 8530004021 332 49 91 (United Kingdom)
A&G Med Trading SRL Tel: +4021 332 49 91
Generics Pharma Hellas ΕΠΕ
Generics Pharma Hellas ΕΠΕ Τηλ: +30 210 9936410
Generiske lægemidler svarende til Zoledronsyre Teva anvendes desuden til behandling af Pagets sygdom hos voksne.
Zoledronic acid Teva Generics is also used to treat Paget’s disease of the bone in adults.
generiske lægemidler svarende til Zoledronsyre Teva zoledronsyre
Zoledronic acid Teva Generics zoledronic acid
Generne ved injektionsstedet var generelt milde, af forbigående karakter og optrådte hovedsageligt efter den første injektion.
The injection site discomfort was generally mild and transient in nature and occurred predominantly after the first injection.
GeneSeq resistensanalyse
GeneSeq resistance assay
Genetisk modificeret rekombinant Stx2e-antigen: ≥ 3,2 x 106 ELISA-enheder
Genetically modified recombinant Stx2e antigen: ≥ 3.2 x 106 ELISA units
Genetisk modificeret rekombinant Stx2e-antigen: ≥ 3,2 x 106 ELISA-enheder
Genetically modified recombinant Stx2e antigen: ≥ 3.2 x 106 ELISA units/ml
Genetisk polymorfi
Genetic Polymorphism
Genetisk rådgivning anbefales også til patienter, der ønsker at få børn efter endt behandling.
Genetic counselling is also recommended for patients wishing to have children after therapy.
Genetisk rådgivning til patienter med BRCA-mutationer bør udføres ifølge lokale retningslinjer.
Genetic counselling for patients with BRCA mutations should be performed according to local regulations.
Genetiske og ikke-genetiske biomarkøranalyser bør implementeres som obligatorisk for alle inkluderede patienter.
Genetic and non-genetic biomarker analysis should be implemented as mandatory for all enrolled patients.
GENETISKE SYGDOMME
GENETIC DISEASES
Genforekomst
Re-occurrence
Genfundet af total radioaktivitet i fæces og urin, efter administration af 14C-tigecyclin, angiver, at 59 % af dosis elimineres via galden og fæces, og 33 % udskilles via urin.
The recovery of the total radioactivity in faeces and urine following administration of 14C-tigecycline indicates that 59 % of the dose is eliminated by biliary/faecal excretion, and 33 % is excreted in urine.
Genfyld ikke din InnoLet.
Do not refill your InnoLet.
Gengivelse af indholdet heri er tilladt med kildeangivelse.
Reproduction is authorised provided the source is acknowledged.
Gengivelse af indholdet heri er tilladt med kildeangivelse.
Reproduction is authorised provided the source is acknowledged. kidney function.
Gengivelse af indholdet heri er tilladt med kildeangivelse.
Reproduction is authorised provided the source is acknowledged. the stomach.
Gengivelse af indholdet heri er tilladt med kildeangivelse. antracycliner og taxaner (en anden type kræftmidler) ikke virker, eller når det ikke er hensigtsmæssigt at gentage behandlingen med antracycliner.
Reproduction is authorised provided the source is acknowledged. on its own when treatment with both anthracyclines and taxanes (another type of anticancer medicine) has failed or when repeat treatment with anthracyclines is not suitable for the patient.
Gengivelse af indholdet heri er tilladt med kildeangivelse. calciumkanalerne.
Reproduction is authorised provided the source is acknowledged. effect on calcium channels.
Gengivelse af indholdet heri er tilladt med kildeangivelse. der giver uændrede doser heraf.
Reproduction is authorised provided the source is acknowledged. strength that continues to provide the same doses.
Gengivelse af indholdet heri er tilladt med kildeangivelse. fjerne det til mindst 24 timer efter at kemoterapien er afsluttet.
Reproduction is authorised provided the source is acknowledged. chemotherapy, and it is removed a minimum of 24 hours after completing chemotherapy.
Gengivelse af indholdet heri er tilladt med kildeangivelse. hvor luftvejene let forsnævres).
Reproduction is authorised provided the source is acknowledged. bronchial hyperresponsiveness (a state in which the airways of the lungs narrow easily).
Gengivelse af indholdet heri er tilladt med kildeangivelse. infektioner) og blodplader (blodkomponenter, der medvirker ved blodets størkning), kan det være nødvendigt at sætte dosis ned eller udskyde behandlingen.
Reproduction is authorised provided the source is acknowledged. that fights infection) and platelets (components that help the blood to clot), the dose may have to be reduced or treatment may have to be delayed.
Gengivelse af indholdet heri er tilladt med kildeangivelse. kan der gives en lavere dosis på 4,5 mg, hvis den højere dosis ikke tåles af patienten, eller hvis lægen anser en lavere dosis for mere hensigtsmæssig.
Reproduction is authorised provided the source is acknowledged. considered more appropriate.
Gengivelse af indholdet heri er tilladt med kildeangivelse. kirtelkræft i maven hos patienter, der endnu ikke har fået nogen medicin mod deres kræft.
Reproduction is authorised provided the source is acknowledged. gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Gengivelse af indholdet heri er tilladt med kildeangivelse. mellemrum.
Reproduction is authorised provided the source is acknowledged. into 2 doses given every 12 hours.
Gengivelse af indholdet heri er tilladt med kildeangivelse. overflade.
Reproduction is authorised provided the source is acknowledged. patient’s total body surface area.
Gengivelse af indholdet heri er tilladt med kildeangivelse.-{}-
Reproduction is authorised provided the source is acknowledged.
Gengivelse af indholdet heri er tillladt med kildeangivelse.
This is the maximum dose.
Genital herpes, folliculitis, gastroenteritis, herpes simplex, herpes virusinfektion, herpes zoster, influenza, byld i lymfeknude, molluscum contagiosum, nasofaryngitis, øvre luftvejsinfektion
genital herpes, folliculitis, gastroenteritis, herpes simplex, herpes virus infection, herpes zoster, influenza, lymph node abscess, molluscum contagiosum, nasopharyngitis, upper respiratory tract infection
genital kløe,
Genital pruritus,
Genital pruritus**
Dizziness
Genital pruritus**
Pruritus genital
genitale vorter og vorter omkring anus
warts on the genitals and around the anus;
genitalkløe (kløende fornemmelse i kønsdelene)
genital pruritus (genital itching sensation)
Genitalt erytem, ejakulationssvigt, paræstesi af mandlige genitalier, penissmerter, penislidelser, genital pruritus
Genital erythema, ejaculation failure, paraesthesia of male genital, penile pain, penis disorder, pruritus genital
Genne msnit
Mean
Genne msnit (SD)
Mean (SD)
gennem 10,7 år hos piger (n=369) og 10,6 år hos drenge (n=326) på 9-15 år på vaccinationstidspunktet (median opfølgning på henholdsvis 10,0 år og 9,9 år);
through 10.7 years in girls (n=369) and 10.6 years in boys (n=326), 9-15 years of age at time of vaccination (median follow-up of 10.0 years and 9.9 years, respectively);
Gennem 360 ugers behandling blev der udført en succesfuld genotype-analyse af virale isolater hos 19 ud af 28 patienter med bekræftet hiv-RNA over 400 kopier/ml og ingen primære eller aktiv site- mutationer i protease (aminosyrer i positionerne 8, 30, 32, 46, 47, 48, 50, 82, 84 og 90) eller proteasehæmmer-fænotyperesistens blev vist.
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance.
gennem 9,6 år hos mænd (n=918) på 16-26 år på vaccinationstidspunktet (median opfølgning på 8,5 år); og gennem 8,4 år hos kvinder (n=684) på 24-45 år på vaccinationstidspunktet (median opfølgning på 7,2 år).
through 9.6 years in men (n=918), 16-26 years of age at time of vaccination (median follow- up of 8.5 years); and through 8.4 years in women (n=684), 24-45 years of age at time of vaccination (median follow-up of 7.2 years).
Gennem 96 uger i SPRING-2 og FLAMINGO-studiet og gennem 144 uger i SINGLE-studiet blev der ikke set tilfælde af behandlingsrelateret primær resistens over for integrase- eller NRTI-klassen i dolutegravir- armene.
Through 96 weeks in SPRING-2 and FLAMINGO and 144 weeks in SINGLE, no cases of treatment emergent primary resistance to the integrase- or NRTI-class were seen in the dolutegravir-containing arms.
Gennem behandlingsforløbet med Herceptin subkutan formulering i injekstionssystem skal andre lægemidler til subkutan administration så vidt muligt injiceres på forskellige steder.
During the treatment course with Herceptin subcutaneous formulation in administration system, other medicinal products for subcutaneous administration should preferably be injected at different sites.
Gennem bindingen til CD25 blokerer basiliximab aktiviteten for interleukin-2 og reducerer dermed den
By binding to CD25, basiliximab blocks the activity of interleukin-2, reducing the rate at which the
gennem en plastikslange, der er indsat i din blodåre (intravenøs infusion) normalt over 90 minutter
through a plastic tube placed in your vein (intravenous infusion) usually over 90 minutes
gennem en sonde i maven kaldet en gastrostomisonde. gennem en sonde i næsen, som går gennem næsen til mavesækken – kaldet en nasogastrisk sonde.
through a tube that goes through your tummy (‘abdomen’) to the stomach - called a ‘gastrostomy tube’ through a tube that goes through your nose to the stomach - called a ‘nasogastric tube’.
Gennem erstatning af de manglende hormoner gør Pergoveris det muligt for kvinder med lave FSH- og LH-niveauer at udvikle en follikel.
By replacing the missing hormones, Pergoveris allows women with low levels of FSH and LH to develop a follicle.
Gennem et studie med et-års follow-up er det påvist, at virknigen af sevelamer på phosphat og kalcium kan vedligeholdes.
The effects of sevelamer on phosphorus and calcium were proven to be maintained throughout a study with one year follow-up.
Gennem et studie med et-års follow-up er det påvist, at virkningen af sevelamer på phosphat og kalcium kan vedligeholdes.
The effects of sevelamer on phosphorus and calcium were proven to be maintained throughout a study with one year follow-up.
Gennem et studie med et-års follow-up er det påvist, at virkningen af sevelamer på phosphat og kalcium kunne vedligeholdes.
The effects of sevelamer on phosphorus and calcium were proven to be maintained throughout a study with one year follow-up.
Gennem post-marketing overvågning i det Antiretrovirale Graviditetsregister, etableret i januar 1989, er der ikke rapporteret en forøget risiko for fødselsdefekter ved eksponering for Kaletra blandt mere end 1000 kvinder, som blev eksponeret i første trimester.
In post-marketing surveillance through the Antiretroviral Pregnancy Registry, established since January 1989, an increased risk of birth defects exposures with Kaletra has not been reported among over 1000 women exposed during the first trimester.
Gennem post-marketing overvågning i det Antiretrovirale Graviditetsregister, etableret i januar 1989, er der ikke rapporteret om forøget risiko for fødselsdefekter ved eksponering for Kaletra blandt mere end 1000 kvinder, som blev eksponeret i første trimester.
In post-marketing surveillance through the Antiretroviral Pregnancy Registry, established since January 1989, an increased risk of birth defects exposures with Kaletra has not been reported among over 1000 women exposed during the first trimester.
Gennem- sigtig cylinder- ampul
Clear Cartridge
Gennem- snit
Median
Gennem- snitlig tid til
Median Time to Failure (months)
Gennem- snitlig ændring i HbA1c fra baseline (%)† (SE)
Mean change from baseline in HbA1c (%)† (SE)
Gennem- snitlige baseline HbA1c (%)
Mean baseline HbA1c (%)
Gennem- snitligt antal oocytter
Mean number of oocytes
Gennembor ikke kapslen mere end én gang.
Do not pierce the capsule more than once.
Gennembrud invasiv svampeinfektion – dag 180
Breakthrough IFI – Day 180
Gennembruds- og pletblødning kan forekomme under behandlingen.
Break-through bleeding and spotting may occur during treatment.
Gennembrudssmerter opstår pludseligt.
Breakthrough pain comes on suddenly.
Gennemføre en randomiseret, kontrolleret fase 3-undersøgelse (PIX306) af pixantron-rituximab versus gemcitabin-rituximab hos patienter med aggressiv B- celle NHL, hos hvem CHOP-R ikke har virket tilfredsstillende, og som ikke er egnede til autolog stamcelletransplantation (ASCT) (andetvalgs), eller hos hvem ASCT (tredje- eller fjerdevalgs) ikke har haft tilfredsstillende virkning.
To conduct a randomised controlled Phase 3 study (PIX306) of pixantrone- rituximab vs gemcitabine-rituximab in patients with aggressive B-cell NHL, who failed front line CHOP-R who are not eligible for autologous stem cell transplant (ASCT) (2nd line) or failed ASCT (3rd or 4th line).
gennemføre et komparativt observationsstudie med henblik på vurdering
ANX 2.1 - The MAH commits to conduct a long-term comparative
Gennemføre et observations-registerstudie med henblik på at indsamle sikkerheds- og virkningsdata hos nyligt diagnostiserede pædiatriske patienter med Ph+ akut lymfoblastær leukæmi (ALL) behandlet med kemoterapi + imatinib ± HSCT.
To conduct an observational registry collecting efficacy and safety data in newly diagnosed paediatric Ph+ Acute Lymphoblastic Leukaemia (ALL) patients treated with chemotherapy + imatinib ± HSCT.
Gennemføres senest
Due date
gennemførte selvmord (se pkt.
Suicide attempt, suicidal ideation and completed suicide (see section 4.4)